- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02140931
Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Study Overview
Detailed Description
This prospective, randomized, double-blind, placebo controlled study will assess the efficacy and safety of autologous ACPs administered intramuscularly into the lower extremity of subjects with CLI who lack surgical or endovascular revascularization options.
A total of approximately 95 subjects will be randomized to treatment with ACP-01 or placebo using a 2:1 randomization scheme, respectively, stratified by site.
The study will continue until all subjects treated experience the study event (either de novo gangrene, doubling of wound size, major amputation, or death) or are event-free for at least 26 weeks. Subjects treated will be followed for no longer than 52 weeks.
One futility analysis for potentially stopping study enrollment will be performed.
Subjects treated at each investigative site will provide written informed consent prior to the conduct of any study-related procedures. Thereafter, they will be screened and those meeting the inclusion/exclusion criteria will be enrolled into the trial and undergo all the study procedures including intramuscular injection of the investigational medicinal product (IMP = ACP-01 or placebo). The IMP will be administered in addition to any conventional treatment the subject is receiving.
The control group will receive placebo injections into the lower extremity to ensure blinding of the assessors and the subjects.
The placebo will consist of the same medium used in the ACP product suspension.
The study consists of four periods: Screening period, Treatment period, Acute safety follow-up and Long term follow-up periods. The total duration of study participation, including follow-up, is at least 26 weeks. Subjects will be followed for up to 52 weeks and at least until the last subject has completed his/her 26 week visit.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1K3
- Vancouver General Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is diagnosed with critical limb ischemia
- Patient has hemodynamic indicators of severe peripheral arterial disease
- Patient is not a candidate for revascularization treatment options for peripheral arterial disease
- Patient is on standard of care medical therapy for peripheral arterial disease
- Male or female age 18 and above
- Non-pregnant, non-lactating female
- Patient is able to understand and provide a signed informed consent form
Exclusion Criteria:
- Patient having an uncorrected Aorto-Iliac occlusive disease down to the origin of the Profunda-Femoris artery
- Patient who in the opinion of the investigator would require a major amputation within approximately 4 weeks after administration of study treatment.
- Critical Limb Ischemia presenting as severe large ischemic ulcers or dry gangrene proximal to the MTP (Metatarsophalangeal) joints heads or lower extremity wet gangrene
- Lower extremity non-treated active infection
- Hypercoagulable state
- Patient received blood transfusions during the previous 4 weeks
- Patient's condition precludes 2 consecutive attempts of ACPs manufacturing
- Patient unable to communicate
- Major non-vascular operation during the preceding 3 months
- Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart failure during the preceding 3 months
- Severe aortic stenosis
- Severe renal failure
- Severe hepatic failure
- Anemia
- Major stroke within the preceding 3 months.
- Diagnosis of malignancy within the preceding 3 years
- Concurrent chronic or acute infectious disease and uncontrolled infectious symptoms
- Severe concurrent disease
- Bleeding diathesis.
- Participation at the same time in another stem cell study
- Chronic immunomodulating or cytotoxic drug treatment
- Fever for 2 days prior to the time the patient is about to receive the study treatment
- Life expectancy of less than 6 months
- Patient unlikely to be available for follow-up
- No acute worsening of CLI (Critical Limb Ischemia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Angiogenic Cell Precursors
Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
|
Intra-muscular injections
|
Placebo Comparator: Cell culture medium
Intra-muscular injections of cell culture medium in the ischemic leg
|
Intra-muscular injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to major amputation / mortality
Time Frame: 26 weeks
|
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in the level of pain in the treated ischemic leg
Time Frame: 26 weeks
|
26 weeks
|
Change from baseline in the quantity of analgesic drugs used by the patient
Time Frame: 26 weeks
|
26 weeks
|
Change from baseline in ABI (Ankle Brachial Index)
Time Frame: 26 weeks
|
26 weeks
|
Change from baseline in TBI (Toe Brachial Index)
Time Frame: 26 weeks
|
26 weeks
|
Change from baseline in quality of life
Time Frame: 26 weeks
|
26 weeks
|
Change from baseline in ulcer size
Time Frame: 26 weeks
|
26 weeks
|
Total hospitalization time of ACP-treated patients compared to controls
Time Frame: 26 weeks
|
26 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of intramuscular injection of ACPs
Time Frame: 26 weeks
|
|
26 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ravi Jain, PhD, Hemostemix Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS 12-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on Injections
-
Vivozon, Inc.CompletedPain, PostoperativeUnited States
-
Medical University of SilesiaCompletedMyalgia | Bruxism | Temporomandibular Disorder | PRPPoland
-
Vivozon Pharmaceutical Inc.CompletedPain, Postoperative | Acute PainKorea, Republic of
-
Vivozon, Inc.CompletedPain, PostoperativeUnited States
-
Gmax Biopharm LLC.RecruitingPulmonary Arterial HypertensionUnited States, China
-
Salus Ltd.TheraVitae Ltd.CompletedCritical Limb IschemiaHungary
-
Vivozon, Inc.CompletedPost-Operative PainUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Completed
-
AnergisTerminatedAllergy | Allergic RhinitisSwitzerland